Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children

Highlights • Adjuvanted (aTIV) and two non-adjuvanted (TIV) vaccines compared in young children. • Enhanced antibody response to aTIV against all homologous and heterologous strains. • Significantly faster (after one dose) and more persistent response to aTIV. • aTIV increasingly superior to TIV wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-10, Vol.32 (46), p.6146-6156
Hauptverfasser:	Nolan, Terry, Bravo, Lulu, Ceballos, Ana, Mitha, Essack, Gray, Glenda, Quiambao, Beatriz, Patel, Sanjay S, Bizjajeva, Svetlana, Bock, Hans, Nazaire-Bermal, Nancy, Forleo-Neto, Eduardo, Cioppa, Giovanni Della, Narasimhan, Vas
Format:	Artikel
Sprache:	eng
Schlagworte:	(www.clinicaltrials.gov): NCT01346592 Adjuvant Adjuvants, Immunologic - administration & dosage Age Allergy and Immunology Antibodies, Viral - blood Antibody Formation Applied microbiology Biological and medical sciences Child, Preschool Children Female Fluad Fundamental and applied biological sciences. Psychology Hemagglutination Inhibition Tests Humans Immunogenicity Infant Infants Infections Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza B virus Influenza vaccine Influenza Vaccines - administration & dosage Influenza Vaccines - therapeutic use Influenza, Human - prevention & control Male MF59 Microbiology Polysorbates - administration & dosage Single-Blind Method Squalene - administration & dosage Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Subunit - administration & dosage Vaccines, Subunit - therapeutic use Viral infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Adjuvanted (aTIV) and two non-adjuvanted (TIV) vaccines compared in young children. • Enhanced antibody response to aTIV against all homologous and heterologous strains. • Significantly faster (after one dose) and more persistent response to aTIV. • aTIV increasingly superior to TIV with increasing HI threshold titer. • Higher reactogenicity of aTIV, offset by increased immunogenicity.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.08.068